EMERYVILLE, Calif., May 2, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a biotech company developing novel anti-infective products for the treatment and prevention of topical infections including those caused by antibiotic-resistant bacterial strains, announced today the publication of key data demonstrating that development of resistance to NovaBay’s lead Aganocide compound, NVC-422, is highly unlikely for a variety of infectious organisms, including methicillin-resistant S. aureus (commonly known as MRSA), compared to traditional antibiotics. Study results were published in the May 2012 issue of Antimicrobial Agents and Chemotherapy1, the journal for the American Society for Microbiology.
